2023 ASCO Highlights

IASLCs Education Committee will present a one-hour live session, synthesizing lung cancer research presented at the recent June meeting of the American Society of Clinical Oncology (ASCO). This webinar will address clinicians need to keep abreast of current research and future trends to inform clinical practice.

Learning Objectives

At the end of the webinar, learners will be able to:

1. Recognize the efficacy and safety of perioperative immune checkpoint inhibitors in patients with resectable NSCLC.
2. Analyze data based on trials using EGFR-TKIs as adjuvant therapy in EGFR positive NSCLC patients.
3. Evaluate the role of immune checkpoint inhibitors in advanced NSCLC harboring EGFR activation mutation.

Dr. Hidehito Horinouchi (Japan) will moderate the program and lead the discussion and Q&A following panel presentations by Jyoti Patel, MD (US), Navneet Singh, MD, PhD (India), and Dr. Stephanie Saw (Singapore). Topics of discussion include perioperative and EGFR positive NSCLC immune checkpoint inhibitors and targeted therapy in resectable disease.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.

The International Association for the Study of Lung Cancer designates the live format for this educational activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.